<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161562</url>
  </required_header>
  <id_info>
    <org_study_id>CIGE025ECA01</org_study_id>
    <nct_id>NCT02161562</nct_id>
  </id_info>
  <brief_title>OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients</brief_title>
  <acronym>OPTIMA</acronym>
  <official_title>OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in CSU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial assessed the efficacy of optimized re-treatment therapy with omalizumab (150mg or
      300mg) after relapse, in participants with Chronic Spontaneous Urticaria who were clinically
      well-controlled following their first course of treatment with omalizumab (150mg or 300mg).
      The study also assessed the benefit of uptitrating to 300mg dose in participants who were not
      well-controlled following their initial course of treatment with omalizumab 150mg, as well as
      the benefit of treatment extension of those patients who were not well-controlled following
      their initial course of treatment with omalizumab 300mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted of 5 phases.

      Phase 1 (Screening): At the first visit (Screening Visit), the participant was provided
      informed consent and then completed all screening visit assessments. During this visit, all
      CIU/CSU treatments taken by the participant were documented. Any protocol-defined prohibited
      CIU/CSU treatments were stopped at this visit, and the participant underwent a wash-out
      period of 1-5weeks (refer to study protocol for medication wash-out times) prior to Phase 2
      Visit1. Only non-sedating H1- antihistamines, at locally-approved dosages, were allowed to be
      continued during the Screening Period and throughout the rest of the study. All participants
      also needed to complete daily diary during the entire screening period.

      Phase 2 (Initial Dosing Period): Following completion of Phase 1, eligible participants were
      randomly assigned (in a 4:3 ratio) to either Group A or Group B. Participants in Group A were
      treated with omalizumab 150mg by subcutaneous (SC) injection every 4 weeks during the 24-week
      Phase 2 (Initial Dosing Period), while participants in Group B were treated with omalizumab
      300mg every 4 weeks during this period. Randomization to treatment groups was stratified at
      Phase 2 Visit 1 by geographic location of the study site (i.e. Canada or Latin America),
      baseline presence/absence of angioedema and baseline UAS7 score (collected at Phase 2 Visit
      1). At the end of Phase 2, all participants with a UAS7 score ≤ 6 entered Phase 3 (Study
      Treatment Withdrawal Period). Group A participants who had a UAS7 &gt; 6 at any visit of Phase 2
      starting at Week 8 (Phase2-Visit3) skipped Phase 3 and moved directly to Phase 4 (Second
      Dosing Period) and received 300 mg Omalizumab (step-up). Group B participants who had a UAS7
      &gt;6 at the end of Phase 2 skipped Phase 3 and moved directly to Phase 4.

      Phase 3 (Study Treatment Withdrawal Period): During Phase 3 (Study Treatment Withdrawal
      Period), no study treatment (omalizumab) was given and participants continued to visit the
      study center at 4-week intervals (to a maximum of 8 weeks). If a UAS7 score ≥16 was observed
      during Phase 3 (Study Treatment Withdrawal Period), the participant moved directly to Phase 4
      (Second Dosing Period). If a participant completed the full 8 weeks of Phase 3 (Study
      Treatment Withdrawal Period) with a UAS7 score &lt;16, the participant was moved directly to
      Phase 5 (Follow-up Period).

      Phase 4 (Second Dosing Period)

        -  Group A participants who relapsed (UAS7 ≥16) during Phase 3 (Study Treatment Withdrawal
           Period) were retreated with omalizumab 150mg by SC injection every 4 weeks during the
           12-week Phase 4 (Second Dosing Period)

        -  Group A participants who were not clinically well-controlled at week 8 of Phase 2
           (Initial Treatment Period) or any subsequent visit in Phase 2 moved to Phase 4 (Second
           Dosing Period) immediately during which their study treatment was up-titrated to 300mg
           by SC injection every 4 weeks for 12 weeks.

        -  Group A participants who had their symptoms well controlled at week 24 (UAS7≤6) but did
           not relapse during the 8 weeks Study Treatment withdrawal period (UAS7&lt;16) moved
           directly to Phase 5, Follow up period.

        -  Group B participants who relapsed during Phase 3 (Study Treatment Withdrawal Period)
           were retreated with omalizumab 300mg by SC injection every 4 weeks during the 12- week
           Phase 4 (Second Dosing Period)

        -  Group B participants who were not clinically well-controlled at week 24 of Phase 2
           (Initial Treatment Period) moved to Phase 4 (Second Dosing Period) immediately during
           which their study treatment remained 300mg by SC injection every 4 weeks for 12 weeks.
           In case the treating physician and the participant decided not to extend treatment, they
           could move directly from Phase 2 (Initial Treatment Period) to Phase 5 (Follow- up
           Period).

        -  Group B participants who had their symptoms well controlled at week 24 (UAS7≤6) but did
           not relapse during the 8 weeks Study Treatment withdrawal period (UAS7&lt;16) moved
           directly to Phase 5, Follow up period.

      Phase 5 (Follow-up Period)

        -  Participants who did not relapse (UAS7 &lt;16) following completion of Phase 3 (Study
           Treatment Withdrawal Period) entered the 4-week Phase 5 (Follow-up Period).

        -  Group B participants who did not respond during their initial 24-week treatment period
           (Phase 2), and who did not wish to extend their treatment into Phase 4 (Second Dosing
           Phase) were allowed to move directly into the 4-week Phase 5 (Follow-up Period).

        -  All participants who completed Phase 4 (Second Dosing Period) entered the 4-week Phase 5
           (Follow-up Period).

      During Phase 5 (Follow-up Period), participants continued to only receive non-sedating H1-
      antihistamines at approved dosages. Omalizumab was not allowed to be administered during this
      period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2014</start_date>
  <completion_date type="Actual">November 3, 2016</completion_date>
  <primary_completion_date type="Actual">November 3, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Were Clinically Well-controlled (UAS7&lt;=6) After the Initial Dosing Period, Relapsed (UAS7&gt;=16) When Treatment Was Discontinued, and Who Achieved a UAS7 Score &lt;=6 at the End of the Second Dosing Period (Retreatment A2 and B2)</measure>
    <time_frame>Last 7 days of second dosing period, 44 weeks</time_frame>
    <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the last 7 days of the second dosing period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Difference in Urticaria Activity Score Over 7 Days (UAS7) Between the Start and End of the Second Dosing Period, in Participants That Step-up Treatment Dose During the Initial Dosing Period (Step-up A3)</measure>
    <time_frame>7 days prior to start of second dosing period and last 7 days of Second Dosing Period</time_frame>
    <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the 7 days prior to the second dosing period, and the last 7 days of the second dosing period. A negative change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Urticaria Activity Score Over 7 Days (UAS7)≤6 at the End of the Second Dosing Period, in Participants Who Stepped-up Treatment Dosing (Step-up A3)</measure>
    <time_frame>Last 7 days of the second dosing period</time_frame>
    <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the last 7 days of the second dosing period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Relapse (Urticaria Activity Score Over 7 Days (UAS7) ≥ 16) After Drug Withdrawal in Participants Who Responded to Initial Dosing Period (Retreatment A2 and B2)</measure>
    <time_frame>study drug withdrawal period, weeks 24 through 32</time_frame>
    <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the time between end of initial dosing period to first occurence of UAS7 ≥ 16 will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Urticaria Activity Score Over 7 Days (UAS7) Between End of Initial Dosing Period and the End of the Second Dosing Period, in Group B3 Participants Who Did Not Respond to the Initial Dosing Period</measure>
    <time_frame>last 7 days of initial dosing period, week 24, and last 7 days of second dosing period, week 36</time_frame>
    <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the last 7 days of the initial dosing period and the last 7 days of the second dosing period. A negative change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Urticaria Activity Score Over 7 Days (UAS7) From Baseline to Week 24 in Group B Participants</measure>
    <time_frame>7 days prior to Baseline visit, and last 7 days prior to week 24 of the initial dosing period</time_frame>
    <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the 7-day period prior to Baseline visit and the last 7 days prior to the week 24 visit of initial dosing period. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urticaria Activity Score Over 7 Days (UAS7) Between Baseline and End of Second Dosing Period</measure>
    <time_frame>7 days prior to Baseline visit, and last 7 days of second dosing period</time_frame>
    <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the 7 days before Baseline and the last 7 days of the second dosing period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Who Remained Well-controlled (UAS7&lt;=6) or Who Had Achieved UAS=0 at Phase 4 (Second Dosing Period) Week 8 During Retreatment After Being Well Controlled or Achieving UAS7=0 at Phase 2 (Initial Dosing Period) Week 8</measure>
    <time_frame>Week 8 of initial dosing phase and week 8 of second dosing phase</time_frame>
    <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from week 8 of initial dosing phase and week 8 of second dosing phase.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">314</enrollment>
  <condition>Chronic Spontaneous Urticaria</condition>
  <arm_group>
    <arm_group_label>omalizumab 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omalizumab 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omalizumab</intervention_name>
    <description>150mg omalizumab via sub-cutaneous injection once every 4 weeks</description>
    <arm_group_label>omalizumab 150mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omalizumab</intervention_name>
    <description>300mg omalizumab via sub-cutaneous injection once every 4 weeks</description>
    <arm_group_label>omalizumab 300mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Men or women at least 18 years of age at time of screening.

          -  Having a diagnosis of CSU and the presence of symptoms for ≥6 months prior to the
             screening visit.

          -  Presence of itch and hives for ≥6 consecutive weeks at any time prior to the screening
             visit despite concurrent use of non-sedating H1-antihistamine treatment

          -  Patient must have been on an approved dose of non-sedating H1-antihistamine for CSU,
             and no other concomitant CSU treatment, for at least the 7 consecutive days
             immediately prior to the randomization visit and must document current use on the day
             of the randomization visit.

        Key Exclusion Criteria:

          -  Patients having a clearly defined underlying etiology for chronic urticaria other than
             CSU including the following urticarias: acute, solar, cholinergic, heat, cold,
             aquagenic, delayed pressure or contact

          -  Patients with other skin disease associated with itch that could interfere with study
             outcomes and/or compromise the safety of the patient

          -  Patients with evidence of parasitic infection

          -  Patients with a history of malignancy of any organ system (other than localized basal
             cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless
             of whether there is evidence of local recurrence or metastases.

          -  Pregnant or nursing (lactating) women,

          -  Women of child-bearing potential, unless they are using effective methods of
             contraception during dosing of study treatment.

          -  Patients who are unable or unwilling to comply with study procedures, attend scheduled
             study visits, complete questionnaires and daily diaries, or who may otherwise be
             unable to comply with the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pilar</city>
        <state>Buenos Aires</state>
        <zip>1629</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <state>Rosario</state>
        <zip>S2000DBS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000CXH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1125ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salta</city>
        <zip>A4400ERH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>40110-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alphaville / Barueri</city>
        <state>Sao Paulo</state>
        <zip>06454-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 4Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3J 3R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 2G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>GIV 4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <zip>M4C 5M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santo Domingo</city>
        <state>Republica Dominicana</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Delegacion Tlalpan</city>
        <state>Distrito Federal</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45190</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Dominican Republic</country>
    <country>Guatemala</country>
    <country>Mexico</country>
    <country>Panama</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2014</study_first_posted>
  <results_first_submitted>October 31, 2017</results_first_submitted>
  <results_first_submitted_qc>October 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2018</results_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic spontaneous urticaria, CSU, chronic idiopathic urticaria, CIU, hives, angioedema, itch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients were randomly assigned in a 4:3 ratio to Group A or Group B.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Omalizumab 150mg (A)</title>
          <description>Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.</description>
        </group>
        <group group_id="P2">
          <title>Omalizumab 300mg (B)</title>
          <description>Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved back to home country</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew due to being out of the country</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved out of province</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omalizumab 150mg (A)</title>
          <description>Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.</description>
        </group>
        <group group_id="B2">
          <title>Omalizumab 300mg (B)</title>
          <description>Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="178"/>
            <count group_id="B2" value="136"/>
            <count group_id="B3" value="314"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="14.03"/>
                    <measurement group_id="B2" value="45.8" spread="13.60"/>
                    <measurement group_id="B3" value="46.3" spread="13.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Clinically Well-controlled (UAS7&lt;=6) After the Initial Dosing Period, Relapsed (UAS7&gt;=16) When Treatment Was Discontinued, and Who Achieved a UAS7 Score &lt;=6 at the End of the Second Dosing Period (Retreatment A2 and B2)</title>
        <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the last 7 days of the second dosing period.</description>
        <time_frame>Last 7 days of second dosing period, 44 weeks</time_frame>
        <population>Participants from groups A2 (n=12) and B2 (n=44) were considered for the analysis. Only Groups A2 and B2 participants, who had UAS7 scores collected at end of the second dosing period, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>All Retreatment (A2&amp;B2)</title>
            <description>omalizumab 150 mg retreatment group + omalizummab 300 mg retreatment group</description>
          </group>
          <group group_id="O2">
            <title>Retreatment (A2)</title>
            <description>omalizumab 150 mg retreatment group</description>
          </group>
          <group group_id="O3">
            <title>Retreatment (B2)</title>
            <description>omalizumab 300 mg retreatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Clinically Well-controlled (UAS7&lt;=6) After the Initial Dosing Period, Relapsed (UAS7&gt;=16) When Treatment Was Discontinued, and Who Achieved a UAS7 Score &lt;=6 at the End of the Second Dosing Period (Retreatment A2 and B2)</title>
          <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the last 7 days of the second dosing period.</description>
          <population>Participants from groups A2 (n=12) and B2 (n=44) were considered for the analysis. Only Groups A2 and B2 participants, who had UAS7 scores collected at end of the second dosing period, were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Difference in Urticaria Activity Score Over 7 Days (UAS7) Between the Start and End of the Second Dosing Period, in Participants That Step-up Treatment Dose During the Initial Dosing Period (Step-up A3)</title>
        <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the 7 days prior to the second dosing period, and the last 7 days of the second dosing period. A negative change indicates improvement.</description>
        <time_frame>7 days prior to start of second dosing period and last 7 days of Second Dosing Period</time_frame>
        <population>Group A3 participants (n=141) were considered for the analysis. Only Group A3 participants, who had UAS7 scores collected at the start and end of the second dosing period, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Step-up Treatment Group (A3)</title>
            <description>Step-up treatment from omalizumab 150 mg to 300 mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Difference in Urticaria Activity Score Over 7 Days (UAS7) Between the Start and End of the Second Dosing Period, in Participants That Step-up Treatment Dose During the Initial Dosing Period (Step-up A3)</title>
          <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the 7 days prior to the second dosing period, and the last 7 days of the second dosing period. A negative change indicates improvement.</description>
          <population>Group A3 participants (n=141) were considered for the analysis. Only Group A3 participants, who had UAS7 scores collected at the start and end of the second dosing period, were analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="10.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Urticaria Activity Score Over 7 Days (UAS7)≤6 at the End of the Second Dosing Period, in Participants Who Stepped-up Treatment Dosing (Step-up A3)</title>
        <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the last 7 days of the second dosing period.</description>
        <time_frame>Last 7 days of the second dosing period</time_frame>
        <population>Group A3 participants (n=141) were considered for the analysis. Only Group A3 participants, who had UAS7 scores collected at the end of the second dosing period, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Step-up Treatment Group (A3)</title>
            <description>Step-up treatment from omalizumab 150 mg to 300 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urticaria Activity Score Over 7 Days (UAS7)≤6 at the End of the Second Dosing Period, in Participants Who Stepped-up Treatment Dosing (Step-up A3)</title>
          <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the last 7 days of the second dosing period.</description>
          <population>Group A3 participants (n=141) were considered for the analysis. Only Group A3 participants, who had UAS7 scores collected at the end of the second dosing period, were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Relapse (Urticaria Activity Score Over 7 Days (UAS7) ≥ 16) After Drug Withdrawal in Participants Who Responded to Initial Dosing Period (Retreatment A2 and B2)</title>
        <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the time between end of initial dosing period to first occurence of UAS7 ≥ 16 will be evaluated.</description>
        <time_frame>study drug withdrawal period, weeks 24 through 32</time_frame>
        <population>The Retreatment participants were analyzed (A2=12, B2=44).</population>
        <group_list>
          <group group_id="O1">
            <title>All Retreatment (A2&amp;B2)</title>
            <description>omalizumab 150 mg retreatment group + omalizummab 300 mg retreatment group</description>
          </group>
          <group group_id="O2">
            <title>Retreatment (A2)</title>
            <description>omalizumab 150 mg retreatment group</description>
          </group>
          <group group_id="O3">
            <title>Retreatment (B2)</title>
            <description>omalizumab 300 mg retreatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse (Urticaria Activity Score Over 7 Days (UAS7) ≥ 16) After Drug Withdrawal in Participants Who Responded to Initial Dosing Period (Retreatment A2 and B2)</title>
          <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the time between end of initial dosing period to first occurence of UAS7 ≥ 16 will be evaluated.</description>
          <population>The Retreatment participants were analyzed (A2=12, B2=44).</population>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="2.37"/>
                    <measurement group_id="O2" value="4.8" spread="2.70"/>
                    <measurement group_id="O3" value="4.7" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Urticaria Activity Score Over 7 Days (UAS7) Between End of Initial Dosing Period and the End of the Second Dosing Period, in Group B3 Participants Who Did Not Respond to the Initial Dosing Period</title>
        <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the last 7 days of the initial dosing period and the last 7 days of the second dosing period. A negative change indicates improvement.</description>
        <time_frame>last 7 days of initial dosing period, week 24, and last 7 days of second dosing period, week 36</time_frame>
        <population>Group B3 participants (n=43) were considered for the analysis. Only B3 participants, who had UAS7 scores collected at both weeks 24 and 44, were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Treatment (B3)</title>
            <description>omalizumab 300 mg extended treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Urticaria Activity Score Over 7 Days (UAS7) Between End of Initial Dosing Period and the End of the Second Dosing Period, in Group B3 Participants Who Did Not Respond to the Initial Dosing Period</title>
          <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the last 7 days of the initial dosing period and the last 7 days of the second dosing period. A negative change indicates improvement.</description>
          <population>Group B3 participants (n=43) were considered for the analysis. Only B3 participants, who had UAS7 scores collected at both weeks 24 and 44, were included in the analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Urticaria Activity Score Over 7 Days (UAS7) From Baseline to Week 24 in Group B Participants</title>
        <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the 7-day period prior to Baseline visit and the last 7 days prior to the week 24 visit of initial dosing period. A negative change from baseline indicates improvement.</description>
        <time_frame>7 days prior to Baseline visit, and last 7 days prior to week 24 of the initial dosing period</time_frame>
        <population>Group B participants (n=136) were considered for the analysis. Only Group B participants, who had both baseline and week 24 UAS7 scores collected, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab 300mg (B)</title>
            <description>Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Urticaria Activity Score Over 7 Days (UAS7) From Baseline to Week 24 in Group B Participants</title>
          <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the 7-day period prior to Baseline visit and the last 7 days prior to the week 24 visit of initial dosing period. A negative change from baseline indicates improvement.</description>
          <population>Group B participants (n=136) were considered for the analysis. Only Group B participants, who had both baseline and week 24 UAS7 scores collected, were analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.8" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urticaria Activity Score Over 7 Days (UAS7) Between Baseline and End of Second Dosing Period</title>
        <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the 7 days before Baseline and the last 7 days of the second dosing period.</description>
        <time_frame>7 days prior to Baseline visit, and last 7 days of second dosing period</time_frame>
        <population>Group A (n=178) and Group B (n=136) participants were considered for the analysis. Only Group A and Group B participants who had both baseline and week 44 UAS7 scores collected, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab 150mg (A)</title>
            <description>Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.</description>
          </group>
          <group group_id="O2">
            <title>Omalizumab 300mg (B)</title>
            <description>Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.</description>
          </group>
          <group group_id="O3">
            <title>Overall (A&amp;B)</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Urticaria Activity Score Over 7 Days (UAS7) Between Baseline and End of Second Dosing Period</title>
          <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from the 7 days before Baseline and the last 7 days of the second dosing period.</description>
          <population>Group A (n=178) and Group B (n=136) participants were considered for the analysis. Only Group A and Group B participants who had both baseline and week 44 UAS7 scores collected, were analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" spread="11.66"/>
                    <measurement group_id="O2" value="-23.0" spread="10.92"/>
                    <measurement group_id="O3" value="-20.6" spread="11.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Who Remained Well-controlled (UAS7&lt;=6) or Who Had Achieved UAS=0 at Phase 4 (Second Dosing Period) Week 8 During Retreatment After Being Well Controlled or Achieving UAS7=0 at Phase 2 (Initial Dosing Period) Week 8</title>
        <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from week 8 of initial dosing phase and week 8 of second dosing phase.</description>
        <time_frame>Week 8 of initial dosing phase and week 8 of second dosing phase</time_frame>
        <population>Only Groups A2 and B2 participants, who had UAS7 scores collected at week 8 of initial dosing period and week 8 of second dosing period, were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>All Retreatment (A2&amp;B2)</title>
            <description>omalizumab 150 mg retreatment group + omalizummab 300 mg retreatment group</description>
          </group>
          <group group_id="O2">
            <title>Retreatment (A2)</title>
            <description>omalizumab 150 mg retreatment group</description>
          </group>
          <group group_id="O3">
            <title>Retreatment (B2)</title>
            <description>omalizumab 300 mg retreatment</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Remained Well-controlled (UAS7&lt;=6) or Who Had Achieved UAS=0 at Phase 4 (Second Dosing Period) Week 8 During Retreatment After Being Well Controlled or Achieving UAS7=0 at Phase 2 (Initial Dosing Period) Week 8</title>
          <description>The UAS7 is a 7-day composite self-reported evaluation of itch (daily score 0-3) plus number of hives (daily score 0-3). The worst possible daily UAS score is 6, and the worst possible UAS7 score is 42. For this outcome, the participant's self-reported UAS7 score will be drawn from week 8 of initial dosing phase and week 8 of second dosing phase.</description>
          <population>Only Groups A2 and B2 participants, who had UAS7 scores collected at week 8 of initial dosing period and week 8 of second dosing period, were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UAS7&lt;=6 at week 8 of the initial dosing period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UAS7=0 at week 8 of the initial dosing period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UAS7&lt;=6 at week 8 of the second dosing period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UAS7=0 at week 8 of the second dosing period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The serious adverse events (SAEs) count for the overall B group = 8 but the sum of the subgroups = 7. Per protocol, the subgroup assignment is based on the UAS7 outcome. The discrepancy mentioned previously is due to the fact that one participant was not assigned to a B subgroup because this participant was discontinued prior to finalizing phase 2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Omalizumab 150 mg (A)</title>
          <description>Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.</description>
        </group>
        <group group_id="E2">
          <title>Maintained Response (A1)</title>
          <description>omalizumab 150 mg maintained response group</description>
        </group>
        <group group_id="E3">
          <title>Retreatment (A2)</title>
          <description>omalizumab 150 mg retreatment group</description>
        </group>
        <group group_id="E4">
          <title>Step-up Treatment Group (A3)</title>
          <description>Step-up treatment from omalizumab 150 mg to 300 mg</description>
        </group>
        <group group_id="E5">
          <title>Omalizumab 300 mg (B)</title>
          <description>Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.</description>
        </group>
        <group group_id="E6">
          <title>Maintained Response(B1)</title>
          <description>omalizumab 300 mg Maintained Response group</description>
        </group>
        <group group_id="E7">
          <title>Retreatment (B2)</title>
          <description>omalizumab 300 mg retreatment</description>
        </group>
        <group group_id="E8">
          <title>Extended Treatment (B3)</title>
          <description>omalizumab 300 mg extended treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Porphyria acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Maternal exposure during pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.0001</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="94" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="109" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="37" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="37" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Eye oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Myopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Breath odour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Lip oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Mouth swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Noninfective gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Reflux gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Burn infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Eye infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Infection parasitic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Bladder injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Spirometry abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Oral fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pyogenic granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Cluster headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vascular headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Emotional distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nasal mucosal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nasal oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Chloasma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dyshidrotic eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Excessive granulation tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hand dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Skin swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Solar lentigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

